Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Ovid Therapeutics (OVID) FCF Margin (2020 - 2025)

Ovid Therapeutics (OVID) has disclosed FCF Margin for 6 consecutive years, with 5.75% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, FCF Margin rose 868032.0% year-over-year to 5.75%, compared with a TTM value of 573.77% through Sep 2025, up 1124358.0%, and an annual FY2024 reading of 9909.89%, up 177914.0% over the prior year.
  • FCF Margin was 5.75% for Q3 2025 at Ovid Therapeutics, up from 75.8% in the prior quarter.
  • Across five years, FCF Margin topped out at 77.21% in Q1 2021 and bottomed at 114180.99% in Q3 2022.
  • Average FCF Margin over 5 years is 13267.69%, with a median of 5364.62% recorded in 2024.
  • Peak annual rise in FCF Margin hit 10487732bps in 2023, while the deepest fall reached -1613580bps in 2023.
  • Year by year, FCF Margin stood at 77.21% in 2021, then crashed by -106bps to 4.56% in 2022, then crashed by -203872bps to 9303.67% in 2023, then plummeted by -42bps to 13192.11% in 2024, then soared by 100bps to 5.75% in 2025.
  • Business Quant data shows FCF Margin for OVID at 5.75% in Q3 2025, 75.8% in Q2 2025, and 4.61% in Q1 2025.